A lung adenocarcinoma patient with ROS1 fusion and NBN germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of ROS1 inhibitors: a case report
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.